Panacea Biotec

Innovation in support of life

June 16, 2020

The Manager, Listing Department The National Stock Exchange of India Ltd. Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 NSE Symbol: PANACEABIO BSE Limited Corporate Relationship Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 BSE Scrip Code: 531349

Reg.: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam.

This is in continuation to our letter dated June 10, 2020, intimating that the Company has entered into a Memorandum of Understanding with REFANA Inc. USA, for global development, manufacturing and distribution of the Covid-19 vaccine.

Pursuant to Regulation 30 of SEBI LODR Regulations, we are pleased to inform you that the Board of Directors of the Company has, at its meeting held today, i.e. June 16, 2020, interalia, considered and approved the following:

- 1. Setting up of a Joint Venture Company in the name of Panacea Refana Ltd. for development, manufacturing and distribution of the Covid-19 vaccine.
- 2. Seeking shareholders' approval through Postal Ballot for:
 - a. investment in the said Joint Venture Company; and
 - b. approval of 'Panacea Biotec Limited Employee Stock Option Plan 2020' for the employees of the Company and its Subsidiary Company, Panacea Biotec Pharma Limited.

We request you to kindly bring the above information to the notice of your members.

Thanking you,

Sincerely yours, For Panacea Biotec Ltd.

Vinod Goel

Group CFO and Head Legal & Company Secretary



B1 Extn. /G3, Mohan Co-op Indl. Estate, Mathura Road, New Delhi -110044 Email: vinodgoel@panaceabiotec.com Phone: D.I.D. +91-11-4167 9015 Fax: +91-11-4167 9070